Description
GDC-0623 is an inhibitor of MEK that prevents MEK-dependent B-Raf and KRAS signaling. GDC-0623 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for several cancers.
GDC-0623
Product ID G1210
Cas No. 1168091-68-6
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1168091-68-6 |
|---|---|
| Purity | ≥98% |
| Formula | C16H14FIN4O3 |
| Formula Wt. | 456.21 |
| IUPAC Name | 5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide |
| Solubility | DMSO 91 mg/mL warmed (199.46 mM) Ethanol 5 mg/mL warmed (10.95 mM) Water Insoluble |
| Appearance | Beige Powder |
Shipping and Storage
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
References
Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6. PMID: 23934108.